Arzneimittel Forsch
-
Arzneimittel Forsch · Jan 2001
Randomized Controlled Trial Clinical TrialDose-related effects of controlled release dihydrocodeine on oro-cecal transit and pupillary light reflex. A study in human volunteers.
It is well accepted that long-term administration of opioids results in a dose-related constipation. No data so far have demonstrated conclusively whether such constipation is also seen after intake of a controlled release formulation. It was therefore of interest to evaluate whether increasing doses of a controlled release formulation of dihydrocodeine (DHC, CAS 125-28-0) after oral administration also induces a dose-related increase in constipation. ⋯ It is concluded that opioid receptor sites, which are located in the plexus myentericus of the intestinal wall, are responsible for the delay in propulsion. Because of the controlled release of a fixed amount of DHC over time there is constant binding of the ligand followed by a constant conformational change of peripheral and central receptor sites. Thus constant release induces no dose-related increase in oro-cecal transit and inhibition of the pupillary light reflex.
-
Arzneimittel Forsch · Jan 2001
Randomized Controlled Trial Comparative Study Clinical Trial[Relative bioavailability of diclofenac after a single administration of a new multiple-unit formulation of enteric-coated pellets].
The relative bioavailability of diclofenac (CAS 15307-86-5) was investigated after a single administration of a multiple-unit formulation containing 75 mg diclofenac sodium in enteric-coated pellets (A) in comparison to an enteric-coated tablet with 50 mg diclofenac sodium (B), a capsule containing 140 mg diclofenac resinate (C) and a dispersible tablet containing 46.5 mg diclofenac acid (D). The study was carried out in a four-way crossover design in 16 healthy male volunteers. Serum concentrations of diclofenac were determined with a validated and specific HPLC-method. ⋯ Despite the enteric-coating of the pellets, a short lagtime of 0.4 h was determined for the test formulation. For the other rapid-release formulation (D), the lagtime was of a similar magnitude (0.3 h), while drug release and absorption from the enteric-coated tablet and the diclofenac resinate capsule were delayed (1.8 and 0.7 h, respectively). Due to the rapid and high bioavailability of diclofenac, the multiple-unit formulation fulfills the prerequisites for the oral treatment of acute painful conditions when prompt analgesic and anti-inflammatory efficacy is desired.
-
Arzneimittel Forsch · Jan 2001
Role of L-arginine/nitric oxide pathway in the antinociceptive activities of morphine and mepyramine in mice.
The p-benzoquinone (PBQ)-induced abdominal constriction test was used to assess the involvement of L-arginine/nitric oxide (NO) pathway in the antinociceptive activity of the subcutaneously administered H1-receptor antagonist, mepyramine (CAS 59-33-6), and an opioid receptor agonist, morphine (CAS 57-27-2), in mice. Mepyramine (ED50: 5.6 mg/kg) and morphine (ED50: 0.13 mg/kg) produced antinociceptive effects. The NO precursor L-arginine (CAS 1119-34-2) (50 mg/kg) also produced antinociception similar to mepyramine, but significantly less than morphine. ⋯ The antinociceptive activity of morphine, but not that of mepyramine, was completely abolished when combined with L-NMMA. L-NMMA also significantly decreased the antinociception induced by morphine or mepyramine in combination with L-arginine. The present results suggest that morphine and mepyramine could produce peripheral antinociception by the involvement of L-arginine/NO cascade or other related pathways of nociceptive processes induced by NO.
-
Arzneimittel Forsch · Jan 2001
Antioxidant effect of N omega-nitro-L-arginine methyl ester (L-NAME) on global cerebral ischemia in a rat model.
The antioxidant effect of the non-specific nitric oxide synthase inhibitor, N omega-nitro-L-arginine methyl ester (CAS 50903-99-6, L-NAME), was studied in a rat model of global cerebral ischemia. In addition, the influence of low doses of L-NAME on nitric oxide production, measured as nitrate/nitrite end products, was investigated in the ischemic rats. Ischemia was induced by bilateral clamping of the common carotid arteries for 60 min followed by a reperfusion period for 60 min. ⋯ L-NAME was also capable to normalize the reduced activity of superoxide dismutase (SOD, 1.15.1.1) that was observed after ischemia. Improvement of these parameters in L-NAME-treated rats was parallel to normalization of nitric oxide production in the treated animals. These results indicate that inhibition of nitric oxide synthase, induced by L-NAME, could improve the oxidative status of the rat brain after ischemia.